Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005
Targeted therapy in nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 284–298 Year: 2009
Nonsmall cell lung cancer Source: Eur Respir Rev 2013; 22: 33-36 Year: 2013
Uncommon EGFR mutations of lung adenocarcinoma in one tertiary institution, Korea: clinical characteristics and treatment response to tyrosine kinase inhibitors Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018
Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015
The “COLD-PCR-approach” for early and cost-effective detection of tyrosine kinase inhibitor resistance Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013
Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer Source: Eur Respir J 2002; 19: 557-570 Year: 2002
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017
Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010
Clinical experience on EGFR tyrosin kinase inhibitor in non-small-cell lung cancer, compassionate programme in the Czech Republic Source: Eur Respir J 2006; 28: Suppl. 50, 782s Year: 2006
TKIs: a new class of drugs in the management of lung cancer Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
The biology of lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=61 Year: 2001
European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology Source: International Congress 2015 – Quality management in lung cancer Year: 2015
Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic. Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
Better quality-of-life in patients with exon 19 deletion receiving first-line tyrosine kinase inhibitors for advanced non-small-cell lung cancer Source: International Congress 2017 – Noteworthy lung cancer patient reports: reported outcome measures, smoking cessation, weight and sleep disorders Year: 2017
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011
Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006
Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study Source: Eur Respir J 2007; 29: 128-133 Year: 2007